Table 1.
Clinical characteristics
| Patient characteristics | NATA (n = 75) | Controls (n = 150) | P value |
|---|---|---|---|
| Recipient median age, y (range) | 59 (23-74) | 57 (18-78) | .65 |
| Recipient age (y), % (n) | |||
| ≤60 | 57 (43) | 60 (90) | .77 |
| >60 | 43 (32) | 40 (60) | |
| HCT CI | |||
| <3 | 61 (46) | 63 (94) | .89 |
| ≥3 | 39 (29) | 37 (56) | |
| Donor type, % (n) | |||
| Related | 31 (23) | 29 (43) | .91 |
| Unrelated | 59 (44) | 61 (92) | |
| Haploidentical | 11 (8) | 10 (15) | |
| Donor cell source, % (n) | |||
| Marrow | 20 (15) | 17 (25) | .81 |
| Peripheral blood | 75 (56) | 77 (116) | |
| Cord | 5 (4) | 6 (9) | |
| Indication, % (n) | |||
| Acute leukemia | 48 (36) | 53 (79) | .62 |
| MDS/MPN | 33 (25) | 27 (40) | |
| Lymphoma | 11 (8) | 14 (21) | |
| Multiple myeloma | 3 (2) | 4 (6) | |
| Nonmalignant | 5 (4) | 3 (4) | |
| Conditioning regimen intensity, % (n) | |||
| Full | 43 (32) | 53 (79) | .20 |
| Reduced | 57 (43) | 47 (71) | |
| GVHD prophylaxis, % (n) | |||
| CNI based | 82 (61) | 85 (128) | .10 |
| Cyclophosphamide based | 13 (10) | 14 (21) | |
| T-cell depletion | 5 (4) | 1 (1) | |
| GVHD serotherapy prophylaxis, % (n) | |||
| ATG | 9 (7) | 32 (48) | <.001 |
| No ATG | 91 (68) | 68 (102) | |
| GVHD characteristics | |||
| Median onset day (range) | 36 (10-231) | 29 (5-174) | .002 |
| Minnesota risk, % (n) | |||
| Standard | 48 (36) | 51 (77) | .67 |
| High | 52 (39) | 49 (73) | |
| Tx GVHD grade, % (n) | |||
| Grade 1 | 8 (6) | 10 (15) | .98 |
| Grade 2 | 35 (26) | 34 (51) | |
| Grade 3 | 45 (34) | 43 (65) | |
| Grade 4 | 12 (9) | 13 (19) | |
| Tx organ involvement | |||
| Skin stage 1-2 ± UGI | 20 (15) | 16 (25) | .37 |
| Skin stage 3-4 ± UGI | 8 (6) | 13 (19) | |
| LGI ± other | 71 (53) | 71 (106) | |
| Liver only | 1 (1) | 0 | |
CNI, calcineurin inhibitor; CI, combordity index; LGI, lower gastrointestinal tract; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; Tx, transplant; UGI, upper gastrointestinal tract.
Significant value is indicated in bold.